BioGaia’s results for the first quarter to exceed market expectations

(Figures in the brackets refer to the same period the previous year)

During the first quarter of 2023, BioGaia's sales have been impacted by increased demand, mainly in the Americas and APAC. The sales in Americas have also been positively impacted by certain one-time effects related to BioGaia starting to sell through its own subsidiary, BioGaia Canada. The sales in APAC have been positively impacted by effects related to the removal of covid restrictions in China.

For the first quarter, sales are preliminarily estimated at SEK 366 million (284), an increase of 29% (excluding foreign exchange effects, 19%). The operating profit for the first quarter is preliminarily estimated at SEK 148 million (95), an increase of 55%.

BioGaia publishes the interim report for the first quarter 2023 on Friday, May 5, 2023, at 08:00 a.m. CEST, followed by an audiocast at 09:30 a.m. CEST.

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Alexander Kotsinas, CFO
Email: [email protected]
Phone: +46 735 00 11 11

Mikaela Idermark Stern, Corporate Communications
Email: [email protected]
Phone: +46 730 95 61 50

About BioGaia AB
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through distribution partners or through our own distribution in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact persons set out above, at 7:00 p.m. CEST on April 26, 2023.